Market Place
Sourcing Support
Xeris` Levoketoconazole Effects In Cushing`s Syndrome At ENDO
03 Jun 2024 //
BUSINESSWIRE
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev
31 Jan 2023 //
BUSINESSWIRE
Xeris Biopharma Announces Recorlev Is Now Commercially Available
31 Jan 2022 //
BUSINESSWIRE
Xeris Biopharma Announces U.S. FDA Approval of Recorlev®
30 Dec 2021 //
BUSINESSWIRE
Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results
29 Oct 2020 //
GLOBENEWSWIRE
Strongbridge Biopharma plc Provides Corporate Update
08 Sep 2020 //
GLOBENEWS WIRE
Strongbridge Biopharma plc Announces Last Patient Completes Last Study V
01 Jul 2020 //
GLOBENEWSWIRE
Strongbridge Biopharma plc Announces $30 M Debt Facility with Avenue Venture
20 May 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.